EICHOR
● Recruiting
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
Condition: Head and Neck Squamous Cell Carcinoma · Sponsor: Merus B.V.
About this study
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
This description comes directly from the study's public registry record.
Talk to the study team
David Yao, MD · +1 617 401 4499 · USenquiries@merus.nl
Eduardo Pennella, MD · +1 617 401 4499 · USenquiries@merus.nl
Always discuss trial participation with your own doctor first.
Locations (218)
| Site 160 | Mobile, Alabama, United States | Recruiting |
| Site 102 | Prescott, Arizona, United States | Completed |
| Site 125 | Scottsdale, Arizona, United States | Recruiting |
| Site 82 | Duarte, California, United States | Recruiting |
| Site 25 | La Jolla, California, United States | Recruiting |
| Site 173 | Orange, California, United States | Recruiting |
| Site 28 | Palo Alto, California, United States | Recruiting |
| Site 127 | Sacramento, California, United States | Recruiting |
| Site 46 | San Francisco, California, United States | Recruiting |
| Site 130 | Lone Tree, Colorado, United States | Recruiting |
| Site 104 | Washington D.C., District of Columbia, United States | Recruiting |
| Site 12 | Fort Myers, Florida, United States | Recruiting |
+ 206 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.